SLC5A2 and obesity disorder: Recent research has indicated that long-acting glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and liraglutide, as well as sodium-glucose cotransporter-2 (SGLT2) inhibitors like empagliflozin, are effective strategies for both weight management and blood sugar control in patients with obesity and related conditions [2].